Jefferies Group’s CytomX Therapeutics CTMX Stock Holding History

Jefferies Group’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-90,000	Closed	-$2.06M	–	2457
2018 Q2	$2.06M	Hold	90,000	–	–	0.01%	876
2018 Q1	$2.56M	Buy	+90,000	New	+$2.57M	0.01%	738

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jefferies Group's CTMX Position: Q4 2019 in Review

Jefferies Group sold out of CytomX Therapeutics (CTMX) in Q4 2019, closing a stake of 29,345 shares — an estimated $217K sold.

Jefferies Group first reported a position in CTMX in Q1 2018 and held it in 3 quarters. The position peaked at $1.29M in Q1 2018. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2019.

Jefferies Group reported no remaining CytomX Therapeutics position as of Q4 2019 after selling out during the quarter.
Jefferies Group sold 29,345 CytomX Therapeutics shares in Q4 2019, an estimated $217K.
Jefferies Group first reported a position in CytomX Therapeutics in Q1 2018 and held it in 3 quarters.
Jefferies Group's CytomX Therapeutics position peaked at $1.29M in Q1 2018.
119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.